Table 2.

In Vitro tested SNEDDS-based TKI formulations.

TKI	Ingredients	Particle Size	Tested Human Cancer Cell Lines	Benefits	Refs.
brigatinib	oleic acid, Tween® 20, diethylene glycol monoethylether	ca. 50 nm	lung adenocarcinoma A549 cells	↑ solubility (205×) ↑ intestinal permeability ↑ anticancer effect	[118]
dasatinib	oleic acid, Cremophor® RH-40, 1,2-propanediol	ca. 16 nm	MDA-MB-231 breast cancer cells	↑ intestinal permeability ↑ anticancer effect	[119]
imatinib	Cremophor® EL, Labrasol® ALF, Lauroglycol™ 90	ca. 47 nm	MDST-8 colon carcinoma cells	↑ anticancer effect	[120]
imatinib	ethyl oleate, Tween® 80, polyethylene glycol 600	ca. 81 nm	MCF-7 breast cancer cells	↑ anticancer effect	[121]
sorafenib	medium-chain triglycerides, lecithin, Tween® 80	ca. 43 nm	HT-29 colorectal adenocarcinoma cells	↑ anticancer effect	[122]
sorafenib	glycerol, Lipoid S75, Tween® 80	75–107 nm	HepG2 liver cancer cells	↑ anticancer effect	[123]
sunitinib	Lauroglycol™ 90, Triton-X100, Transcutol®-P	ca. 42 nm	HT-29 colorectal adenocarcinoma cells	↑ anticancer effect	[124]